Friday, September 08, 2023
Procyrion, a dedicated medical device company committed to enhancing the outcomes of patients suffering from cardiac and renal issues, proudly announces its successful acquisition of new inpatient hospital ICD-10-PCS procedure codes specific to its groundbreaking Aortix™ percutaneous mechanical circulatory support (pMCS) technology.
This achievement marks a significant milestone for the company, coinciding with its upcoming US IDE pivotal trial, the DRAIN-HF (Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure) study, which aims to assess the Aortix system's performance in patients experiencing acute decompensated heart failure (ADHF).
These recently introduced codes encompass three critical aspects: implantation, revision, and removal procedures for a short-term external heart pump positioned in the descending thoracic aorta. Aortix is a catheter-based pump strategically placed in the descending thoracic aorta, designed to relieve the heart's workload, enhance cardiac function, and improve kidney perfusion.
The forthcoming DRAIN-HF pivotal trial (NCT05677100) will thoroughly evaluate the Aortix pump's safety and efficacy compared to the current standard of care, which involves high-dose IV diuretics. This trial targets patients hospitalized due to ADHF, who exhibit persistent congestion and diuretic resistance despite receiving optimal medical management. Aortix has the potential to expedite decongestion and substantially enhance kidney function in these critically ill patients, with the possibility of reducing heart failure rehospitalizations and mortality rates.
Source: prnewswire.com
